219 related articles for article (PubMed ID: 33983674)
1. A DNA damage repair gene-associated signature predicts responses of patients with advanced soft-tissue sarcoma to treatment with trabectedin.
Moura DS; Peña-Chilet M; Cordero Varela JA; Alvarez-Alegret R; Agra-Pujol C; Izquierdo F; Ramos R; Ortega-Medina L; Martin-Davila F; Castilla-Ramirez C; Hernandez-Leon CN; Romagosa C; Vaz Salgado MA; Lavernia J; Bagué S; Mayodormo-Aranda E; Vicioso L; Hernández Barceló JE; Rubio-Casadevall J; de Juan A; Fiaño-Valverde MC; Hindi N; Lopez-Alvarez M; Lacerenza S; Dopazo J; Gutierrez A; Alvarez R; Valverde C; Martinez-Trufero J; Martín-Broto J
Mol Oncol; 2021 Dec; 15(12):3691-3705. PubMed ID: 33983674
[TBL] [Abstract][Full Text] [Related]
2. Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study.
Schöffski P; Taron M; Jimeno J; Grosso F; Sanfilipio R; Casali PG; Le Cesne A; Jones RL; Blay JY; Poveda A; Maki RG; Nieto A; Tercero JC; Rosell R
Eur J Cancer; 2011 May; 47(7):1006-12. PubMed ID: 21376569
[TBL] [Abstract][Full Text] [Related]
3. ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma.
Italiano A; Laurand A; Laroche A; Casali P; Sanfilippo R; Le Cesne A; Judson I; Blay JY; Ray-Coquard I; Bui B; Coindre JM; Nieto A; Tercero JC; Jimeno J; Robert J; Pourquier P
Cancer; 2011 Aug; 117(15):3445-56. PubMed ID: 21287534
[TBL] [Abstract][Full Text] [Related]
4. Analysis of DNA repair-related genes in breast cancer reveals CUL4A ubiquitin ligase as a novel biomarker of trabectedin response.
García MJ; Saucedo-Cuevas LP; Muñoz-Repeto I; Fernández V; Robles MJ; Domingo S; Palacios J; Aracil M; Nieto A; Tercero JC; Benítez J
Mol Cancer Ther; 2013 Apr; 12(4):530-41. PubMed ID: 23364677
[TBL] [Abstract][Full Text] [Related]
5. Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum.
Massuti B; Cobo M; Camps C; Dómine M; Provencio M; Alberola V; Viñolas N; Rosell R; Tarón M; Gutiérrez-Calderón V; Lardelli P; Alfaro V; Nieto A; Isla D
Lung Cancer; 2012 Jun; 76(3):354-61. PubMed ID: 22197612
[TBL] [Abstract][Full Text] [Related]
6. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
7.
Moura DS; Sanchez-Bustos P; Fernandez-Serra A; Lopez-Alvarez M; Mondaza-Hernandez JL; Blanco-Alcaina E; Gavilan-Naranjo A; Martinez-Delgado P; Lacerenza S; Santos-Fernandez P; Carrasco-Garcia I; Hidalgo-Rios S; Gutierrez A; Ramos R; Hindi N; Taron M; Lopez-Guerrero JA; Martin-Broto J
Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32365979
[TBL] [Abstract][Full Text] [Related]
8. Trabectedin in advanced soft tissue sarcoma: case series.
Demirci U; Buyukberber S; Yetisyigit T; Dizdar O; Benekli M; Alkis N; Coskun U;
J BUON; 2012; 17(3):591-2. PubMed ID: 23033305
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
[TBL] [Abstract][Full Text] [Related]
10. Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis.
Schmitt T; Keller E; Dietrich S; Wuchter P; Ho AD; Egerer G
Mar Drugs; 2010 Oct; 8(10):2647-58. PubMed ID: 21116412
[TBL] [Abstract][Full Text] [Related]
11. Trabectedin as a chemotherapy option for patients with BRCA deficiency.
Monk BJ; Lorusso D; Italiano A; Kaye SB; Aracil M; Tanović A; D'Incalci M
Cancer Treat Rev; 2016 Nov; 50():175-182. PubMed ID: 27710871
[TBL] [Abstract][Full Text] [Related]
12. Retrospective inter- and intra-patient evaluation of trabectedin after best supportive care for patients with advanced translocation-related sarcoma after failure of standard chemotherapy.
Araki N; Takahashi S; Sugiura H; Ueda T; Yonemoto T; Takahashi M; Morioka H; Hiraga H; Hiruma T; Kunisada T; Matsumine A; Kawai A
Eur J Cancer; 2016 Mar; 56():122-130. PubMed ID: 26845175
[TBL] [Abstract][Full Text] [Related]
13. Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas.
Laroche A; Chaire V; Le Loarer F; Algéo MP; Rey C; Tran K; Lucchesi C; Italiano A
J Hematol Oncol; 2017 Apr; 10(1):84. PubMed ID: 28399901
[TBL] [Abstract][Full Text] [Related]
14. Trabectedin for the management of soft-tissue sarcoma.
Boudou L; Baconnier M; Blay JY; Lombard-Bohas C; Cassier PA
Expert Rev Anticancer Ther; 2009 Jun; 9(6):727-37. PubMed ID: 19496709
[TBL] [Abstract][Full Text] [Related]
15. What makes real world outcomes in soft tissue sarcomas? A mono-institutional trabectedin experience.
Moriceau G; Vallard A; Méry B; Rivoirard R; Langrand-Escure J; Espenel S; Ben Mrad M; Wang G; Diao P; Fournel P; Collard O; Magné N
Bull Cancer; 2015 Oct; 102(10):814-22. PubMed ID: 26384694
[TBL] [Abstract][Full Text] [Related]
16. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.
Le Cesne A; Blay JY; Domont J; Tresch-Bruneel E; Chevreau C; Bertucci F; Delcambre C; Saada-Bouzid E; Piperno-Neumann S; Bay JO; Mir O; Ray-Coquard I; Ryckewaert T; Valentin T; Isambert N; Italiano A; Clisant S; Penel N
Lancet Oncol; 2015 Mar; 16(3):312-9. PubMed ID: 25680558
[TBL] [Abstract][Full Text] [Related]
17. Trabectedin for the treatment of advanced metastatic soft tissue sarcoma.
Simpson EL; Rafia R; Stevenson MD; Papaioannou D
Health Technol Assess; 2010 May; 14 Suppl 1():63-7. PubMed ID: 20507805
[TBL] [Abstract][Full Text] [Related]
18. Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer.
Carter NJ; Keam SJ
Drugs; 2007; 67(15):2257-76. PubMed ID: 17927287
[TBL] [Abstract][Full Text] [Related]
19. Mapping the literature: role of trabectedin as a new chemotherapy option in advanced pretreated soft tissue sarcoma.
Le Cesne A; Domont J; Cioffi A; Bonvalot S; Terrier P; Ray-Coquard I; Alfaro V; Lebedinsky C; Santabarbara P; Blay JY
Drugs Today (Barc); 2009 Jun; 45(6):403-21. PubMed ID: 19649331
[TBL] [Abstract][Full Text] [Related]
20. Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials.
Cesne AL; Judson I; Maki R; Grosso F; Schuetze S; Mehren MV; Chawla SP; Demetri GD; Nieto A; Tanovic A; Blay JY
Br J Cancer; 2013 Oct; 109(7):1717-24. PubMed ID: 24022187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
